2@H&}6L_L>@D{JE-HIB)-.<?3*&
SYSTEM PROCESSING...
2@H&}6L_L>@D{JE-HIB)-.<?3*&
SYSTEM PROCESSING...
Posted: 2025-04-19 22:13:55 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-04-19 22:14:13 UTC
Verified By
Rollup News
This phase 1 trial investigates the safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in patients with refractory/relapsed large B cell lymphoma, demonstrating promising initial results.
CAR-NK cell therapy shows potential in treating refractory/relapsed large B cell lymphoma.
The therapy utilizes 4-1BB co-stimulation to enhance CAR-NK cell activity.
Phase 1 trial indicates safety and feasibility of the approach.
Refractory/relapsed nature of large B cell lymphoma.
Potential toxicities associated with CAR-NK cell therapy.